PharmaShots | Incisive News in 3 Shots

Subscribe Now

Approved

Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Exelixis Cabometyx (cabozantinib) + Opdivo (nivolumab) Receives US FDA's Approval as a 1L Treatment for Patients with Advanced Ren...

January 25, 2021

AstraZeneca and MSD's Lynparza (olaparib) Receive EU's Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receive EU's Approval as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Canc...

November 6, 2020

World's First App-Based Nicotine Addiction Treatment Receives the MHLW's Approval in Japan

World's First App-Based Nicotine Addiction Treatment Receives the MHLW's Approval in Japan

August 31, 2020

Amgen and Allergan's Kanjinti (biosimilar- trastuzumab) Receive the US FDA's Approval for All Approved Indications of Herceptin

Amgen and Allergan's Kanjinti (biosimilar- trastuzumab) Receive the US FDA's Approval for All Approved Indications of Herceptin

June 14, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us